Urotensin receptor (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database
暂无分享,去创建一个
D. Webb | H. Krum | H. Vaudry | S. Douglas | A. Davenport | M. Maclean | E. Ohlstein | D. Lambert | J. Leprince | A. Fournier | D. Vaudry | A. Giaid | W. Thomas | H. Tostivint
[1] Gerd Krause,et al. Urolinin: The First Linear Peptidic Urotensin-II Receptor Agonist. , 2016, Journal of medicinal chemistry.
[2] Jérôme Leprince,et al. International Union of Basic and Clinical Pharmacology. XCII. Urotensin II, Urotensin II–Related Peptide, and Their Receptor: From Structure to Function , 2015, Pharmacological Reviews.
[3] M. Létourneau,et al. Biochemical and pharmacological characterization of nuclear urotensin‐II binding sites in rat heart , 2012, British journal of pharmacology.
[4] Jérôme Leprince,et al. Urotensin II, from fish to human , 2010, Annals of the New York Academy of Sciences.
[5] C. Reynolds,et al. Nonpeptide urotensin-II receptor antagonists: a new ligand class based on piperazino-phthalimide and piperazino-isoindolinone subunits. , 2009, Journal of medicinal chemistry.
[6] U. Hacksell,et al. Novel and potent small-molecule urotensin II receptor agonists. , 2009, Bioorganic & medicinal chemistry.
[7] H. Vaudry,et al. Characterization of urotensin II, distribution of urotensin II, urotensin II‐related peptide and UT receptor mRNAs in mouse: evidence of urotensin II at the neuromuscular junction , 2008, Journal of neurochemistry.
[8] H. Sarau,et al. Urotensin-II receptor antagonists: synthesis and SAR of N-cyclic azaalkyl benzamides. , 2008, Bioorganic & medicinal chemistry letters.
[9] H. Vaudry,et al. [Orn5]URP acts as a pure antagonist of urotensinergic receptors in rat cortical astrocytes , 2008, Peptides.
[10] T. Sugo,et al. Another ligand fishing for G protein-coupled receptor 14 Discovery of urotensin II-related peptide in the rat brain , 2008, Peptides.
[11] U. Hacksell,et al. Design, parallel synthesis and SAR of novel urotensin II receptor agonists. , 2007, European journal of medicinal chemistry.
[12] H. Vaudry,et al. Structure-activity relationships of a novel series of urotensin II analogues: identification of a urotensin II antagonist. , 2006, Journal of medicinal chemistry.
[13] S. Douglas,et al. A role for urotensin II in restenosis following balloon angioplasty: use of a selective UT receptor blocker. , 2005, Journal of molecular and cellular cardiology.
[14] Urotensin II acts as a modulator of mesopontine cholinergic neurons , 2005, Brain Research.
[15] Jian Jin. Aminoalkoxybenzyl Pyrrolidines as Novel Human Urotensin‐II Receptor Antagonists. , 2005 .
[16] David G. Behm,et al. Nonpeptidic urotensin‐II receptor antagonists I: in vitro pharmacological characterization of SB‐706375 , 2005, British journal of pharmacology.
[17] S. Henriksen,et al. Urotensin II Modulates Rapid Eye Movement Sleep through Activation of Brainstem Cholinergic Neurons , 2005, The Journal of Neuroscience.
[18] Richard R. Neubig,et al. International Union of Pharmacology. XLVI. G Protein-Coupled Receptor List , 2005, Pharmacological Reviews.
[19] U. Hacksell,et al. Isochromanone-based urotensin-II receptor agonists. , 2005, Bioorganic & medicinal chemistry.
[20] M. Clozel,et al. Pharmacology of the Urotensin-II Receptor Antagonist Palosuran (ACT-058362; 1-[2-(4-Benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea Sulfate Salt): First Demonstration of a Pathophysiological Role of the Urotensin System , 2004, Journal of Pharmacology and Experimental Therapeutics.
[21] N. Aiyar,et al. Identification and pharmacological characterization of native, functional human urotensin‐II receptors in rhabdomyosarcoma cell lines , 2004, British journal of pharmacology.
[22] H. Krum,et al. Differential Effect of Urotensin II on Vascular Tone in Normal Subjects and Patients With Chronic Heart Failure , 2004, Circulation.
[23] H. Krum,et al. Urotensin-II as a novel therapeutic target in the clinical management of cardiorenal disease. , 2004, Current opinion in investigational drugs.
[24] D. Johns,et al. From 'gills to pills': urotensin-II as a regulator of mammalian cardiorenal function. , 2004, Trends in pharmacological sciences.
[25] E. Novellino,et al. Urantide: an ultrapotent urotensin II antagonist peptide in the rat aorta , 2003, British journal of pharmacology.
[26] Nobuyuki Miyajima,et al. Identification of urotensin II-related peptide as the urotensin II-immunoreactive molecule in the rat brain. , 2003, Biochemical and biophysical research communications.
[27] T. Klabunde,et al. Functional and Binding Characterizations of Urotensin II-Related Peptides in Human and Rat Urotensin II-Receptor Assay , 2003, Journal of Pharmacology and Experimental Therapeutics.
[28] H. Krum,et al. Direct Actions of Urotensin II on the Heart: Implications for Cardiac Fibrosis and Hypertrophy , 2003, Circulation research.
[29] Y. Hinokio,et al. Role of urotensin II gene in genetic susceptibility to Type 2 diabetes mellitus in Japanese subjects , 2003, Diabetologia.
[30] David G. Behm,et al. Deletion of the UT receptor gene results in the selective loss of urotensin‐II contractile activity in aortae isolated from UT receptor knockout mice , 2003, British journal of pharmacology.
[31] H. Sarau,et al. The neuromedin B receptor antagonist, BIM‐23127, is a potent antagonist at human and rat urotensin‐II receptors , 2003, British journal of pharmacology.
[32] T. Yoshimoto,et al. Urotensin II is an autocrine/paracrine growth factor for the porcine renal epithelial cell line, LLCPK1. , 2003, Endocrinology.
[33] Pierre Renard,et al. Structure–Activity Relationships of Human Urotensin II and Related Analogues on Rat Aortic Ring Contraction , 2003, Journal of enzyme inhibition and medicinal chemistry.
[34] R. Leduc,et al. Photolabelling the rat urotensin II/GPR14 receptor identifies a ligand-binding site in the fourth transmembrane domain. , 2003, The Biochemical journal.
[35] S. A. Douglas,et al. Endoscopic assisted external approach anterior ethmoidal artery ligation for the management of epistaxis , 2003, The Journal of Laryngology & Otology.
[36] Y. Nakashima,et al. Urotensin II-induced activation of extracellular signal-regulated kinase in cultured vascular smooth muscle cells: involvement of cell adhesion-mediated integrin signaling. , 2003, Life sciences.
[37] O. Nayler,et al. The Expression of Urotensin II Receptor (U2R) is Up‐regulated by Interferon‐γ , 2003, Journal of receptor and signal transduction research.
[38] S. Douglas,et al. Chapter 11. Urotensin-II receptor modulators , 2003 .
[39] J. Taylor,et al. Structural requirements at the N-terminus of urotensin II octapeptides , 2002, Peptides.
[40] D. Webb,et al. No effect on central or peripheral blood pressure of systemic urotensin II infusion in humans. , 2002, British journal of clinical pharmacology.
[41] U. Hacksell,et al. Discovery of the first nonpeptide agonist of the GPR14/urotensin-II receptor: 3-(4-chlorophenyl)-3-(2- (dimethylamino)ethyl)isochroman-1-one (AC-7954). , 2002, Journal of medicinal chemistry.
[42] A. Davenport,et al. Is urotensin‐II the new endothelin? , 2002, British journal of pharmacology.
[43] N. Dun,et al. Urotensin‐II regulates intracellular calcium in dissociated rat spinal cord neurons , 2002, Journal of neurochemistry.
[44] David G. Behm,et al. Pharmacological characterization of SB‐710411 (Cpa‐c[D‐Cys‐Pal‐D‐Trp‐Lys‐Val‐Cys]‐Cpa‐amide), a novel peptidic urotensin‐II receptor antagonist , 2002, British journal of pharmacology.
[45] E. Kostenis,et al. A new ligand for the urotensin II receptor , 2002, British journal of pharmacology.
[46] E. Novellino,et al. A new, potent urotensin II receptor peptide agonist containing a Pen residue at the disulfide bridge. , 2002, Journal of medicinal chemistry.
[47] Patricia Andrade-Gordon,et al. Structure-function analysis of urotensin II and its use in the construction of a ligand-receptor working model. , 2002, Angewandte Chemie.
[48] N. Aiyar,et al. Molecular and pharmacological characterization of genes encoding urotensin‐II peptides and their cognate G‐protein‐coupled receptors from the mouse and monkey , 2002, British journal of pharmacology.
[49] T. Klabunde,et al. Identification of nonpeptidic urotensin II receptor antagonists by virtual screening based on a pharmacophore model derived from structure-activity relationships and nuclear magnetic resonance studies on urotensin II. , 2002, Journal of medicinal chemistry.
[50] D. Coy,et al. Human urotensin II-induced aorta ring contractions are mediated by protein kinase C, tyrosine kinases and Rho-kinase: inhibition by somatostatin receptor antagonists. , 2002, European journal of pharmacology.
[51] D. Webb,et al. High plasma concentrations of human urotensin II do not alter local or systemic hemodynamics in man. , 2002, Cardiovascular research.
[52] O. Nayler,et al. UROTENSIN II MEDIATES ERK1/2 PHOSPHORYLATION AND PROLIFERATION IN GPR14-TRANSFECTED CELL LINES , 2002, Journal of receptor and signal transduction research.
[53] J. Pernow,et al. Urotensin II evokes potent vasoconstriction in humans in vivo , 2002, British journal of pharmacology.
[54] Y. Zou,et al. Urotensin II induces hypertrophic responses in cultured cardiomyocytes from neonatal rats , 2001, FEBS letters.
[55] T. Katagiri,et al. Synergistic Effect of Urotensin II With Mildly Oxidized LDL on DNA Synthesis in Vascular Smooth Muscle Cells , 2001, Circulation.
[56] J. Bertoglio,et al. Human Urotensin II–Induced Contraction and Arterial Smooth Muscle Cell Proliferation Are Mediated by RhoA and Rho-Kinase , 2001, Circulation research.
[57] R. Silvestre,et al. Effect of Leptin on Insulin, Glugacon and Somatostatin Secretion in the Perfused Rat Pancreas , 2001, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.
[58] S. Douglas,et al. Potent vasodilator responses to human urotensin-II in human pulmonary and abdominal resistance arteries. , 2001, American journal of physiology. Heart and circulatory physiology.
[59] P. Molenaar,et al. Cardiostimulant effects of urotensin‐II in human heart in vitro , 2001, British journal of pharmacology.
[60] H. Sarau,et al. Differential vasoconstrictor activity of human urotensin‐II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey , 2000, British journal of pharmacology.
[61] H. Nothacker,et al. Human urotensin II mediates vasoconstriction via an increase in inositol phosphates. , 2000, European journal of pharmacology.
[62] A. Davenport,et al. Orphan‐receptor ligand human urotensin II: receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin‐1 , 2000, British journal of pharmacology.
[63] Jilly F. Evans,et al. Identification of urotensin II as the endogenous ligand for the orphan G-protein-coupled receptor GPR14. , 1999, Biochemical and biophysical research communications.
[64] M Kurihara,et al. Urotensin II is the endogenous ligand of a G-protein-coupled orphan receptor, SENR (GPR14). , 1999, Biochemical and biophysical research communications.
[65] Yumiko Saito,et al. Identification of the natural ligand of an orphan G-protein-coupled receptor involved in the regulation of vasoconstriction , 1999, Nature Cell Biology.
[66] H. Sarau,et al. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14 , 1999, Nature.
[67] H. Vaudry,et al. Cloning, sequence analysis and tissue distribution of the mouse and rat urotensin II precursors , 1999, FEBS letters.
[68] H. Vaudry,et al. Cloning of the cDNA encoding the urotensin II precursor in frog and human reveals intense expression of the urotensin II gene in motoneurons of the spinal cord. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[69] R. Balment,et al. Native urotensins influence cortisol secretion and plasma cortisol concentration in the euryhaline flounder, platichthys flesus. , 1998, General and comparative endocrinology.
[70] D. Bergsma,et al. Orphan G protein-coupled receptors: a neglected opportunity for pioneer drug discovery. , 1997, Trends in pharmacological sciences.
[71] H. Vaudry,et al. Somatostatin- and urotensin II-related peptides: molecular diversity and evolutionary perspectives , 1997, Regulatory Peptides.
[72] N. Hazon,et al. Distribution and molecular forms of urotensin II and its role in cardiovascular regulation in vertebrates. , 1996, The Journal of experimental zoology.
[73] H. Heng,et al. Cloning and chromosomal mapping of three novel genes, GPR9, GPR10, and GPR14, encoding receptors related to interleukin 8, neuropeptide Y, and somatostatin receptors. , 1995, Genomics.
[74] D. Thompson,et al. A novel putative neuropeptide receptor expressed in neural tissue, including sensory epithelia. , 1995, Biochemical and biophysical research communications.
[75] H. Vaudry,et al. Spasmogenic actions of frog urotensin II on the bladder and ileum of the frog, Rana catesbeiana. , 1994, General and comparative endocrinology.
[76] J. Frère,et al. Importance of the two tryptophan residues in the Streptomyces R61 exocellular DD-peptidase. , 1992, The Biochemical journal.
[77] Hideshi Kobayashi,et al. Vasopressor effects of urotensin II in rats , 1992 .
[78] Masa-aki Ito,et al. Contraction of rat thoracic aorta strips by endothelin‐1 in the absence of extracellular Ca2+ , 1991, British journal of pharmacology.
[79] H. Bern,et al. The influence of urotensin II on calcium flux in rat aorta , 1988, The Journal of pharmacy and pharmacology.
[80] H. Itoh,et al. Functional receptors for fish neuropeptide urotensin II in major rat arteries. , 1988, European journal of pharmacology.
[81] A. Gibson. Complex effects of Gillichthys urotensin II on rat aortic strips , 1987, British journal of pharmacology.
[82] J. Rivier,et al. Contraction of major artery segments of rat by fish neuropeptide urotensin II. , 1987, The American journal of physiology.
[83] H. Bern,et al. Cardiovascular effects of urotensin II in anesthetized and pithed rats. , 1986, General and comparative endocrinology.
[84] T. Deguchi,et al. Cloning and sequence analysis of cDNAs encoding precursors of urotensin II-alpha and -gamma , 1986, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[85] P. Poulin,et al. Radioimmunoassays for fish tail neuropeptides: II. Development of a specific and sensitive assay for and the occurrence of immunoreactive urotensin II in the central nervous system and blood of Catostomus commersoni. , 1986, Journal of pharmacological methods.
[86] H. Bern,et al. Both somatostatin and the caudal neuropeptide, urotensin II, stimulate lipid mobilization from coho salmon liver incubated in vitro , 1986, Regulatory Peptides.
[87] C. Loretz,et al. Ion transport in goby intestine: cellular mechanism of urotensin II stimulation. , 1985, The American journal of physiology.
[88] R. Nishioka,et al. Neurohormones from fish tails: the caudal neurosecretory system. I. "Urophysiology" and the caudal neurosecretory system of fishes. , 1985, Recent progress in hormone research.
[89] K. Lederis. The fish urotensins: hypophyseal and peripheral actions in fishes and mammals , 1984 .
[90] J. Botting,et al. Neuropeptide-induced contraction and relaxation of the mouse anococcygeus muscle. , 1984, Proceedings of the National Academy of Sciences of the United States of America.
[91] R. Nishioka,et al. Urotensin II: a somatostatin-like peptide in the caudal neurosecretory system of fishes. , 1980, Proceedings of the National Academy of Sciences of the United States of America.
[92] H. Hidaka,et al. Pharmacological Analysis of Urotensin-induced Contraction and Relaxation in Isolated Rabbit Aortas , 1979 .
[93] H. Bern,et al. A reference preparation for the study of active substances in the caudal neurosecretory system of teleosts. , 1969, The Journal of endocrinology.